Table 4.
Clinicopathological features of nodal EBV‐negative CTL with younger and older onset age
| <60 y (n = 22) (n [%]) | >60 y (n = 36) (n [%]) | P | |
|---|---|---|---|
| Age at diagnosis (years) median (range) | 52 (29‐60) | 72 (61‐88) | <.001 |
| Sex (male/female) | 12/10 | 18/18 | .79 |
| PS >1 | 9/20 (45) | 12/29 (41) | 1.0 |
| Clinical stage III/IV | 14/22 (63) | 30/35 (85) | .10 |
| B symptoms | 6/20 (30) | 19/33 (57) | .088 |
| Extranodal site > 1 site | 5/22 (23) | 8/36 (22) | 1.0 |
| Extranodal sites | |||
| Bone marrow | 2/21 (9) | 9/34 (26) | .17 |
| Liver | 2/22 (9) | 4/36 (11) | 1.0 |
| Skin and/or soft tissue | 1/22 (4) | 6/36 (16) | .24 |
| GI tract | 2/22 (9) | 1/36 (2) | .55 |
| Hemophagocytosis | 1/18 (5) | 6/33 (18) | .40 |
| IPI_high‐intermediate/high | 7/22 (31) | 27/32 (84) | <.001 |
| PIT group 3/4 | 7/22 (31) | 31/32 (96) | <.001 |
| Hb < 13 g/dL (male) or Hb < 11 g/dL (female) | 12/18 (66) | 13/33 (39) | .083 |
| Platelets < 130 × 109/L | 3/18 (16) | 14/33 (42) | .073 |
| Serum LDH > normal | 13/21 (61) | 29/35 (82) | .11 |
| CRP > normal | 13/18 (72) | 28/30 (93) | .086 |
| Prior immunosuppressive drug therapy | 2/18 (11) | 2/29 (6) | .63 |
| History of autoimmune disease | 1/18 (5) | 2/29 (6) | 1.0 |
| Treatment | |||
| No therapy | 1/22 (5) | 1/36 (2) | 1.0 |
| CT with anthracycline | 13/19 (68) | 32/36 (88) | .17 |
| CT without anthracycline | 5/19 (26) | 3/36 (8) | .22 |
| ASCT | 7/22 (31) | 1/36 (2) | .003 |
| Response | |||
| CR | 13/20 (65) | 7/29 (24) | .007 |
| PR | 2/20 (10) | 8/29 (27) | .17 |
| NR | 5/20 (25) | 14/29 (48) | .25 |
| Morphology | |||
| Centroblastoid | 8/19 (44) | 12/31 (38) | .77 |
| Pleomorphic | 6/19 (33) | 8/31 (26) | .84 |
| Mixed | 5/19 (26) | 7/31 (22) | 1.0 |
| Unspecified | 0/19 (0) | 4/31 (12) | .28 |
| Immunophenotype | |||
| nPD‐L1 | 2/7 (28) | 1/12 (8) | .52 |
| miPD‐L1 | 3/7 (42) | 7/12 (58) | .65 |
| TIA‐1 | 19/22 (86) | 31/36 (86) | 1.0 |
| Granzyme B | 16/21 (76) | 22/34 (64) | .55 |
| cyCD3 | 19/21 (90) | 30/36 (83) | .70 |
| CD4 | 10/21 (47) | 17/33 (51) | 1.0 |
| CD5 | 15/22 (68) | 16/33 (48) | .18 |
| CD8 | 3/21 (14) | 11/34 (32) | .21 |
| CD30 | 10/17 (58) | 14/28 (50) | .76 |
| CD56 | 5/22 (22) | 4/36 (11) | .28 |
| TCR phenotype | |||
| αβ | 7/17 (41) | 16/30 (53) | .55 |
| γδ | 2/17 (11) | 2/30 (6) | .61 |
| TCR‐silent | 4/17 (23) | 8/30 (26) | 1.0 |
| NK‐cell type | 4/17 (23) | 4/30 (13) | .44 |
ASCT, autologous stem cell transplantation; CR, complete remission; CRP, C‐reactive protein; CT, chemotherapy; CTL, cytotoxic molecule(CM)‐positive peripheral T‐cell lymphoma; cyCD3, cytoplasmic CD3; EBV, Epstein‐Barr virus; GI tract, gastrointestinal tract; Hb, hemoglobin; IPI, International Prognostic Index; LDH, lactate dehydrogenase; miPD‐L1, microenvironmental PD‐L1; NK, natural killer; nPD‐L1, neoplastic PD‐L1; NR, no response; PIT, prognostic index for PTCL; PR, partial remission; PS, performance status; TCR, T‐cell receptor.